. Author manuscript; available in PMC: 2015 Aug 28.

Published in final edited form as: N Engl J Med. 2008 Jun 6;358(24):2545–2559. doi: 10.1056/NEJMoa0802743

Table 2. Prescribed Glucose-Lowering Drugs.^*.

Drug Class and Name	Intensive Therapy (N = 5128)		Standard Therapy (N = 5123)
	no. of patients (%)	person-years	no. of patients (%)	person-years
Single class

Metformin	4856 (94.7)	14,444	4452 (86.9)	12,693

Secretagogue^†	4443 (86.6)	12,021	3779 (73.8)	10,059

Glimepiride	4010 (78.2)	9,142	3465 (67.6)	8,955

Repaglinide	2574 (50.2)	4,447	908 (17.7)	1,293

Thiazolidinedione^‡	4702 (91.7)	12,844	2986 (58.3)	6,719

Rosiglitazone	4677 (91.2)	12,639	2946 (57.5)	6,563

α-Glucosidase inhibitor^§	1191 (23.2)	941	263 (5.1)	200

Incretin^¶	911 (17.8)	566	251 (4.9)	175

Exenatide	622 (12.1)	415	204 (4.0)	155

Any insulin	3965 (77.3)	11,902	2837 (55.4)	7,842

Any bolus insulin	2834 (55.3)	6,806	1794 (35.0)	4,336

Combination of classes

No. of classes without insulin

1 or 2	2798 (54.6)	2,011	3224 (62.9)	6,612

3	3030 (59.1)	3,681	1681 (32.8)	2,545

4 or 5	539 (10.5)	332	109 (2.1)	67

No. of classes with insulin

0	916 (17.9)	829	892 (17.4)	1,495

1 or 2	3311 (64.6)	6,603	2375 (46.4)	5,284

3	2668 (52.0)	4,126	834 (16.3)	1,027

4 or 5	526 (10.3)	344	64 (1.2)	36

Metformin, glimepiride, repaglinide, rosiglitazone, acarbose, and exenatide were provided by a study-supervised formulary. Patients could receive more than one medication or combination of medications and may therefore be counted in more than one category. All individual medications that are listed were prescribed to at least 10% of patients in either group.

^†

Patients received glimepiride, glyburide, gliclazide, repaglinide, or nateglinide.

^‡

Patients received rosiglitazone or pioglitazone.

^§

All the patients in this category received acarbose except one who received miglitol.

^¶

Patients received exenatide or sitagliptin.

Table 2. Prescribed Glucose-Lowering Drugs.*.

Table 2. Prescribed Glucose-Lowering Drugs.^*.